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Abstract
Background: Increased use of prostate specific antigen (PSA) has been associated with increased
prostate cancer incidence. Ireland is estimated to have one of the highest prostate cancer
incidences in Europe and has no national guidelines for prostate cancer screening. GPs have a
pivotal role in influencing PSA testing, therefore, our aim was to describe GP testing practices and
to identify factors influencing these.
Methods: A postal survey, including questions on clinical practice and experience, knowledge and
demographics was distributed to all GPs (n = 3,683). The main outcomes were (i) PSA testing
asymptomatic men and (ii) "inappropriate" PSA testing, defined as testing asymptomatic men aged
< 50 or > 75 years. Factors associated with these outcomes were identified using logistic
regression.
Results: 1,625 GPs responded (response rate corrected for eligibility = 53%). Most respondents
(79%) would PSA test asymptomatic men. Of these, 34% and 51% would test asymptomatic men <
50 and > 75 years, respectively. In multivariate analyses, GPs were more likely to test asymptomatic
men if they were ≥ 50 years, in practice ≥ 10 years, female or less knowledgeable about PSA
efficacy. Male GPs who would have a PSA test themselves were > 8-times more likely to PSA test
asymptomatic men than GPs who would not have a test. GPs who had an asymptomatic patient
diagnosed with prostate cancer following PSA testing, were > 3-times more likely to test
asymptomatic men. Practice-related factors positively associated with testing included: running
'well man' clinics, performing occupational health checks and performing other tests routinely with
PSA. Factors positively associated with 'inappropriate' testing included; being male and willing to
have a PSA test, having worked/trained in the UK and supporting annual PSA testing. 91% of
respondents supported the development of national PSA testing guidelines.
Conclusion: Our findings suggest that widespread PSA testing of asymptomatic men in primary
care is primarily due to a combination of clinical experience, poor knowledge and the support of
doctors for PSA testing, as evidenced by the willingness of male doctors to have a PSA test. There
is an urgent need for education and support for GPs concerning prostate cancer screening, starting
with the implementation of national guidelines.
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Background
Screening for prostate cancer remains an important and
controversial public health issue. Prostate specific antigen
(PSA) testing of asymptomatic men, de facto screening, is
increasingly common in many developed countries [1,2].
This escalating use of PSA testing has driven the increases
in prostate cancer incidence that began to be seen in the
1990s, and continues to be observed [3,4]. However, a
recent Cochrane review confirmed that evidence on the
efficacy of PSA testing as a prostate cancer screening tool
is still lacking [5] and mortality data from two large ran-
domised control trials is a number of years away [6,7].
Thus, the question posed by Ransohoff and colleagues in
2002 [8] remains pertinent – why is prostate cancer
screening so common when the evidence is so uncertain?
The majority of PSA tests originate in primary care [9,10].
While other factors such as urologists practice [11], local
guidelines [11], patient demand [12], a man's social net-
work [13] and the media [11-13] influence the frequency
of PSA testing, GPs have a pivotal role in determining lev-
els and patterns of testing in the population. Improving
understanding of the triggers for PSA testing of asympto-
matic men is, therefore, of considerable importance, espe-
cially if there is to be any possibility of evidence-based
practice in this area.
Several studies have examined influences on GPs' atti-
tudes towards PSA testing or prostate cancer screening.
Patient- (including age [14], smoking-status [14], marital
status [12-15]) and physician-related factors (including
age [14], gender [13-16], non-solo practices [14-17], pos-
itive attitude towards screening for prostate cancer [15],
belief in the efficacy of prostate cancer treatment [18],
agreement with guidelines and being in private practice
[19]) have been identified. However, most have emerged
from univariate analyses and it is unclear whether each
acts independently. In addition, all of the studies were
performed in countries where guidelines are in place
regarding the use of PSA testing, although whether these
influence PSA testing practices is uncertain [16,17,19,20].
It would, therefore, be valuable to investigate the multi-
dimensional nature of GP-related triggers for PSA testing
of asymptomatic men in a setting where there are no "bar-
riers" influencing GPs' attitudes and practices.
In Ireland, which has a mixed public-private healthcare
system there was, until recently, no national policy or
guidelines on PSA testing or prostate cancer screening; in
2006 the National Cancer Forum recommended against
the introduction of a population-based prostate cancer
screening programme [21]. PSA testing is on the increase;
during 1999 to 2004, the number of PSA tests performed
rose by almost 4-fold [9]. This was greater than the
increase observed in Northern Ireland [2], where the NHS
Executive and the National Screening Committee guide-
lines recommend against screening asymptomatic men
[22]. These trends mean that Ireland is predicted to have
had the highest rate of prostate cancer incidence in Europe
in 2006 [23]. It was against this background that we inves-
tigated factors associated with active PSA testing of asymp-
tomatic men among GPs.
Methods
Questionnaire
A self-administered postal questionnaire (Additional file
1) was developed with the aim of assessing the beliefs,
practices, knowledge, and information needs of GPs
regarding prostate cancer and PSA testing. Questions were
included on personal and practice characteristics, knowl-
edge of prostate cancer risk factors, including increasing
age [24], family history of prostate cancer [25], high die-
tary fat intake [26], African American ethnicity [27] and
PSA test properties (e.g. positive predictive value (PPV)
[28], PSA testing practice, and patient management or
referral following abnormal PSA results. As regards PSA
practice, GPs were asked 'Do you usually use PSA to test
asymptomatic men for prostate cancer? and if so, in what
age groups (30 to 80 years and older). GPs were also asked
'Would you consider having a PSA test done yourself in
the future?' The questionnaire was pre-tested on 12 GPs
for acceptability, ease of completion, and to determine
whether any important issues had been omitted, and
revised accordingly. The final instrument consisted of 37
closed questions, 11 patient management scenarios [29]
and a box for written comments, over 12 A4 pages. A copy
of the questionnaire is available from the authors by
request.
Settings, subjects and questionnaire administration
Thirty-six laboratories measure PSA in the Republic of Ire-
land [11]. There are 38 practicing urologists for a popula-
tion of 2.1 million men of all ages.
As described elsewhere, we created a database of all GPs
believed to be practicing in the Republic of Ireland [30].
Briefly, a comprehensive, computerised, list was compiled
from the Irish Medical Directory 2005/2006 (IMD), tele-
phone directories, health authority lists of GPs with con-
tracts to provide services to the Health Service Authority
and a list, maintained by the National Cancer Registry,
Ireland (NCR) since its establishment in 1994, of GPs
who had referred cancer patients. This compiled list was
compared with the membership directory of the Irish Col-
lege of General Practitioners (ICGP). Our final list
included 3,683 GPs.
Three weeks before questionnaires were dispatched, a pre-
contact letter was sent to each GP informing them about
the study and that they would be receiving the question-BMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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naire [30]. The questionnaire was then sent to all 3,683
GPs, together with a pre-paid return envelope. Question-
naires were assigned numerical codes to ensure confiden-
tiality. Those who had not returned the questionnaire
after four weeks were sent a reminder. If necessary, a sec-
ond reminder was sent after a further four weeks. Each
reminder contained another copy of the questionnaire
and pre-paid envelope. No inducements were offered for
questionnaire completion.
During the course of the study, 590 GPs were found to be
ineligible (retired, died, moved and another address was
unavailable, did not see male patients > 40 years, or
included twice) and excluded. The analysis, therefore,
relates to 3,093 GPs.
To ascertain whether there was a difference between
responders and non-responders regarding their PSA prac-
tice and beliefs, an abbreviated 1-page survey consisting of
8 key questions selected from the main questionnaire was
sent to 34% (500/1,468) randomly selected non-respond-
ers, with a pre-paid return envelope.
Outcomes and statistical analysis
The primary outcome was whether, or not, GPs usually
used PSA to test asymptomatic men for prostate cancer. To
investigate factors associated with 'inappropriate' PSA
testing [31] defined for this study as testing asymptomatic
men outside the age groups recommended by most pub-
lished guidelines, the secondary outcome related to
whether or not GPs usually tested 'asymptomatic' < 50 or
> 75 years.
The analysis was based on those who responded to the full
questionnaire and was done in Stata V 8.2 (StataCorp,
2003). Chi-square tests were used to assess univariate
associations between (i) responders and non-responders
to the full questionnaire and (ii) characteristics of the par-
ticipants and the primary and secondary outcomes. Mul-
tivariate logistic regression were used to compute odds
ratios (OR) and 95% confidence intervals for factors asso-
ciated with the primary and secondary outcomes.
Responses to all questions were considered as potential
explanatory variables. The models were adjusted for vari-
ables which were associated with questionnaire response
and those GP characteristics (gender; age; year of gradua-
tion; having qualifications in geriatric medicine, palliative
care and occupational health; whether worked or trained
in the UK; having a specialist interest in men's health,
research, urological problems or cancer detection) and
practice characteristics (being a fulltime principal; solo
verses multi-doctor practice; percentage of patients having
private health insurance; percentage of time performing
occupational health assessments; involvement in GP
training; running 'well man' clinics and having a policy on
PSA testing) for which the likelihood ratio test p-value was
< 0.1 were included in the models. Several factors were
reduced to dichotomous variables for the purposes of
analysis; age of GP (< 50, > 50 years), the age at which PSA
testing usually starts; whether (1% to > 75%) or not (0%)
they performed occupational health checks; preferred fre-
quency of PSA testing (annual or more frequent verses less
frequent testing (biennially, more than biennially, when a
man develops symptoms)); whether or not they refer men
to a urologist at a PSA level ≥ 7 ng/ml (only 5% of
respondents reported that they would refer a 55 year old
man to a urologist at a PSA level of 2.5–3.9 ng/ml, 3%
would refer a 65 year old man at this PSA level); whether
they did, or did not, overestimate the PPV of PSA alone,
and PSA with digital rectal exam (DRE), defined as 25%
and 48%, respectively, in a meta-analysis [28]. A score
based on the seven questions related to prostate cancer
risk factors was built by summing up the number of cor-
rect answers. Interactions between variables were investi-
gated: none were sufficiently important or meaningful in
statistical terms or as regards interpretation to justify
incorporation into the final models. Because of the inter-
relationships between factors in the questionnaire (partic-
ularly GPs' personal and practice characteristics), we took
particular care to avoid multicollinearity in the model fit-
ting. We computed variance inflation factors and toler-
ances for the variables in the final models; all had low
variance inflation factors and high tolerance suggesting
collinearity was not a problem. Model fit was assessed
using the Hosmer and Lemeshow's test and the final mod-
els had adequate fit.
We assumed a priori that the questionnaire response rate
would be 50%. Assuming that 65% of respondents would
be willing, and 35% unwilling, to test asymptomatic men
[16], and adjusting for a variance inflation factor of 1.4
[32], the study would have 88% power to detect as statis-
tically significant a multivariate odds ratio of 1.5 associ-
ated with a risk/explanatory factor prevalent in one-third
of the GPs unwilling to test asymptomatic men (α = 0.05,
two-sided test).
Results
Response rate and participants' characteristics
The response rate for the full questionnaire was 53%
(1,625/3,093). Responders and non-responders did not
differ by gender (p = 0.711), but did differ by year of grad-
uation and practice area; GPs who graduated before 1970
or worked in the Eastern Regional Health Authority,
which includes the capital city, Dublin, were significantly
less likely to participate (p < 0.001). All multivariate anal-
yses were, therefore, adjusted for age and health board
area.BMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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Characteristics of the responding GPs are presented in
Table 1. The demographic and practice characteristics of
respondents did not differ from that described by
O'Dowd et al (2005) [33].
Almost half of responders to the survey had worked or
trained in another country (49%), the majority of these in
the UK (72%). Just over one-third of respondents (34%)
were actively involved in teaching and 70% undertook
occupational health assessments. Fourteen percent of
responding GPs had held a postgraduate post in urology.
Of the respondents, 14% reported that they had a special-
ised interest in mens' health, while 7% and 3% had spe-
cialist interests in cancer detection and urological
problems, respectively. The practices of 17% of GPs held
a "well man" clinic or something similar. Sixty percent of
GPs attended an educational meeting where PSA was a
main topic, 27% of these within the year prior to the sur-
vey.
Knowledge of prostate cancer risk factors and PSA test 
properties
Just over one-third (35%) of respondents correctly
answered 4 or more of the 7 questions on prostate cancer
risk factors, 2% correctly answered all seven questions.
The majority of respondents correctly identified increas-
ing age as a prostate cancer risk factor, while 20% and
76%, respectively, were unaware that having a first degree
relative with prostate cancer and having a high dietary fat
intake increases a man's risk of developing the disease
(Table 2). Over half (56%) responded that smoking was a
risk factor and 28% incorrectly described benign prostate
hyperplasia as increasing prostate cancer risk. Only 17%
of respondents recognised that African American ethnicity
was associated with a higher risk of prostate cancer.
More than half of GPs (54%) overestimated the likeli-
hood that a positive PSA result indicated prostate cancer
(PPV > 30% [28]) and 68% overestimated the PPV of PSA
and DRE (PPV > 50% [28]) combined (Table 3).
PSA testing practice
More than three-quarters of respondents (79%) reported
that they would usually use PSA to test asymptomatic men
for prostate cancer. Two thirds of these GPs (65%) would
test asymptomatic men outside the recommended age-
ranges; 34% and 51% would test men younger than 50
years and older than 75 years, respectively. Of the
respondents, 69% would frequently PSA test a man
attending with lower urinary tract symptoms, 80% would
frequently PSA test a man with a family history of prostate
cancer, 11% would frequently test men with a family his-
tory of breast cancer and 32% would PSA test a man as
part of an occupational health assessment. Almost one-
third of GPs frequently actively arrange appointments for
PSA testing (29%) and 55% perform other blood tests
routinely with PSA.
Most GPs (90%) reported that they frequently inform the
patient that his PSA is being checked. Only 5% frequently
ask about ejaculation in the week preceding a PSA test,
28% sometimes and 14% rarely or never discuss the
implications of an abnormal test, prior to conducting the
test. Twelve percent frequently discuss prostate cancer
treatment, prior to testing.
The majority of male GPs (88%), both younger (84%)
and older (91%) than 50 years, reported that they would
have a PSA test themselves.
Forty percent of all respondents believe men should be
PSA tested biennially, while 30% support annual or more
frequent testing. GPs who believe that testing men less fre-
quently than biennially (11%) or only when symptoms
develop (16%) were in the minority.
Information needs
More than two-thirds of GPs (69%) wanted information
on PSA testing. Overall 82% requested information on at
least one of the topics listed, 36% wanted information on
all topics (Table 4). The overwhelming majority of
respondents were in favour of national guidelines on
prostate cancer screening (92%) and PSA testing in gen-
eral practice (91%).
Table 1: Characteristics of responding GPs
Demographic characteristic Number (%)
Gender Male 1094 (67%)
Female 529 (33%)
Full time principals  Yes 1287 (79%)
Age (years) ≤ 39 305 (19%)
40–49 516 (32%)
50–59 534 (33%)
> 60 253 (16%)
Time in general practice (years) ≤ 5 139 (9%)
6–10 196 (12%)
11–20 488 (30%)
21–30 480 (30%)
> 30 293 (18%)
No. sessions as a GP Per week ≤ 5 156 (10%)
6–8 391 (24%)
9–11 875 (54%)
> 11 150 (9%)
No. GPs per practice 1 575 (35%)
> 1 990 (61%)
Missing 59 (4%)
Area of practice ERHA 478 (29%)
MICGP Yes 1063 (65%)
MICGP: Member of the Irish College of General Practitioners
ERHA: Eastern Regional Health AuthorityBMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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Factors associated with the PSA testing behaviour of GPs
In the multivariate model, female GPs, full-time princi-
pals, those older than 50 years, in practice more than ten
years, or who had a specialist interest in cancer detection,
were significantly more likely to usually test asympto-
matic men (p < 0.05) (Table 5). GPs who undertook occu-
pational health assessments and whose practice offered
well-man clinics were more than 50% more likely to usu-
ally test asymptomatic men.
GPs that had an asymptomatic patient diagnosed with
prostate cancer through a PSA test were 3.31-times more
likely to test asymptomatic men than those who had not.
In further analysis we found that this effect was particu-
larly pronounced among older GPs; compared to GPs
aged < 50 who had not has a patient diagnosed with pros-
tate cancer through a PSA test, GPs aged ≥ 50 who had had
such a patient were 6-times more likely to routinely PSA
test asymptomatic men (multivariate OR = 6.11, 95% CI
3.96–9.25).
Male GPs who would have a PSA test were 8.25-times
more likely to test asymptomatic men than GPs who
would not have a test; this was the highest OR from the
multivariate model.
GPs who were actively involved in teaching were 39% less
likely to usually test asymptomatic men and the likeli-
hood of testing was reduced by 61% among GPs with an
active interest in research. Doctors who overestimated the
PPV of PSA and/or DRE, those who favoured annual or
more frequent testing for men 50 years and older, and
those with a personal or practice PSA testing policy had a
greater likelihood of testing asymptomatic men. Respond-
ents with a greater knowledge of prostate cancer risk fac-
tors were less likely to usually test asymptomatic men in
univariate analyses, however, this association was not sig-
nificant following adjustment for other factors. There was
no relationship between the desire for more information
about PSA and testing behaviour, in either univariate or
multivariate analyses.
The percentage of patients with medical cards (which are
means-tested and entitle the bearer to receive certain
health services, including GP visits, free of charge) or with
private health insurance was not associated with PSA test-
ing practice in the multivariate model. Whether the GP
had trained in the UK, worked in a solo or multi-doctor
practice, had attended an education meeting on PSA, or
had an interest in men's health was unrelated to the like-
lihood of testing.
Table 2: Knowledge of prostate cancer risk factors; we asked GPs 'For each of the following, please indicate whether you believe they 
influence the risk of developing prostate cancer.
Risk factor Correct
N (%)
Does not effect risk
N (%)
Reduces risk
N (%)
Increases risk
N (%)
Don't know
N (%)
Missing
N (%)
Increased age (> 50 years) 1,592 (98%) 8 (0.5%) 3 (0.2%) 1,592 (98%) 4 (0.2%) 18 (1%)
1st degree relative with prostate cancer 1,300 (80%) 97 (6%) 3 (0.2%) 1,300 (80%) 184 (11%) 41 (3%)
Current smoking 263 (16%) 263 (16%) 3 (0.2%) 908 (56%) 386 (24%) 65 (4%)
High dietary fat intake 386 (24%) 391 (24%) 8 (0.5%) 386 (24%) 777 (48%) 63 (4%)
1st degree relative with breast cancer 298 (18%) 533 (33%) 2 (0.1%) 298 (18%) 725 (45%) 67 (4%)
Benign Prostatic Hyperplasia 857 (53%) 857 (53%) 13 (0.8%) 452 (28%) 247 (15%) 56 (3%)
African American ethnicity 284 (17%) 109 (7%) 104 (6%) 284 (17%) 1,078 (66%) 50 (3%)
Table 3: Knowledge of the positive predictive value of PSA and Digital Rectal Exam (DRE); we asked 'For the following tests, what is 
the likelihood that a positive result indicates prostate cancer (positive predictive value)?'
Test < 10%
N (%)
10–30%
N (%)
30–50%
N (%)
> 50%
N (%)
Not sure
N (%)
Missing
N (%)
PSA level 107 (7%) 464 (29%) 491 (30%) 396 (24%) 91 (6%) 76 (5%)
DRE and PSA 6 (0.4%) 67 (4%) 277 (17%) 1,110 (68%) 96 (6%) 69 (4%)BMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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GPs who test asymptomatic men had a very favourable
attitude towards regular testing – they were 5.54-times
more likely to believe that men should have annual or
more frequent PSA testing than GPs who would not test
asymptomatic men.
There was no significant association observed between
those GPs who believed that aggressive treatment (prosta-
tectomy and/or radiotherapy) or those who believed that
non-aggressive treatment (watchful waiting and/or hor-
mone therapy) was more appropriate for the treatment of
prostate cancer, and the likelihood of PSA testing asymp-
tomatic men (OR 0.93 95%CI = 0.68,1.28).
Factors associated with favouring PSA testing younger or 
older asymptomatic men
In the secondary analysis, GPs who trained or worked in
the UK, had a positive attitude towards regular testing
(annual or less), who perform other tests routinely with
PSA, who had a policy on PSA testing and who would
refer a young man (55 years) to a urologist at a lower PSA
level (≤ 7 ng/ml) were all independent factors associated
with the inappropriate use of PSA (Table 6). Male GPs
who would have a PSA test were twice as likely to PSA test
asymptomatic men younger than 50 years and older than
75 years. GPs with an MD or an occupational health qual-
ification were less likely to inappropriately use PSA. Hav-
ing an asymptomatic patient diagnosed with prostate
cancer detected via PSA testing was not significantly asso-
ciated with PSA testing in these age groups, in the multi-
variate model. The models were re-run to investigate,
separately, the factors influencing whether GPs would
routinely test asymptomatic men younger than 50 years
and 75 and older, and the results did not differ to any
great extent (data not shown).
Non-response bias
The brief 1-page survey was returned by 175 of the sample
of 500 non-responders to whom it was sent (35%), taking
the combined response rate to the full questionnaire or
the abbreviated survey to 58%. These 175 GPs were signif-
icantly more likely to i) be older (> 50 years, p = 0.023),
ii) test asymptomatic men (p = 0.007) iii) PSA test men
younger than 40 years (p = 0.008), and iv) to PSA test men
older than 75 years (p = 0.034) and v) were also more
likely to have a PSA test themselves (p = 0.112) than
responders to the initial survey instrument.
Discussion
In the absence of national guidelines, this survey shows
that the routine practice of most GPs working in Ireland is
to test asymptomatic men for prostate cancer by PSA test-
ing. PSA testing [1,2], along with other factors including
biopsy and TURP practices [34], have lead to an increase
in the detection of prostate cancer [3,4]. Given that the
international consensus is either negative or neutral on
the value of prostate screening [35], the undoubted finan-
cial [36], physical [37] and mental [38] costs, and the fact
that Ireland is predicted to have had the highest prostate
cancer incidence in Europe in 2006 [23], it is important to
identify the determinants of this testing behaviour and to
enquire as to methods which might address it.
A dominant theme emerging from this survey is the
approach of GPs to clinical decision-making. Our results
indicate that younger GPs, those involved in education
and research and those with more information on PSA
and prostate cancer were less likely to test asymptomatic
men, although, interestingly, they were not more discrim-
inating with regard to the age at testing. Older GPs,
women (whose routine exposure to prostate cancer is
likely to be infrequent), those with less education and
research exposure seemed to be more likely to perhaps
trust their clinical experience, however limited. We sug-
gest that these beliefs were sincerely held, and unlikely to
be due to either patient demand or method of reimburse-
ment, as evidenced by the GPs' own willingness to
undergo PSA testing and also the lack of difference in test-
ing practices observed between private patients (reim-
bursed on a fee-per-item basis) and public patients
(capitation).
How has it come about that the majority of Irish GPs hold
beliefs which seem in conflict with the scientific evidence?
Many of the GPs responding to this survey were not well
informed about prostate cancer or PSA efficacy. Unavaila-
bility of information seems an implausible explanation;
the internet has placed a vast volume of information, orig-
inal papers, reviews and guidelines at the fingertips of
even the most isolated GP. In addition, our study has
shown that, in contrast to the findings in Northern Ireland
Table 4: Information needs; we asked GPs 'Do you feel you need 
more information with regard to:'
Topics Yes
N (%)
PSA Testing 1,116 (69%)
Prostate cancer risk factors 1,164 (72%)
Prostate cancer diagnosis/detection 1,034 (64%)
Prostate cancer treatment 931 (57%)
Prostate cancer survival 823 (51%)
All of the above 589 (36%)BMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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Table 5: Factors significantly associated with the propensity of GPs to testing asymptomatic men
Yes Total Univariate Multivariate
Num % Num OR [95%CI] OR [95%CI]
GP Characteristics
Gender Male 867 79.7 1,088 1.00 1.00
Female 408 79.1 516 0.96 [0.74,1.25] 1.49 [1.08,2.05]
p = 0.016
Age group < 50 years 604 74.3 813 1.00 1.00
≥ 50 years 660 85.1 776 1.97 [1.53,2.54] 1.71 [1.27,2.31]
p = 0.002
Full-time principal Yes 1,038 81.4 1,275 1.00 1.00
No 225 71.9 313 0.58 [0.44,0.78] 0.57 [0.41,0.81]
p = 0.006
Length of Practice1 ≤ 10 years 235 70.6 333 1 1
11–20 years 366 75.9 482 1.32 [0.96,1.80] 1.45 [1.02,2.07]
21–30 years 406 85.5 475 2.45 [1.73,3.47] 2.39 [1.60,3.56]
≥ 30 years 248 86.1 288 2.59 [1.72,3.89] 2.51 [1.57,4.03]
p < 0.001
Special interest in:
Research No 1,251 80.2 1,559 1.00 1.00
Yes 24 53.3 45 0.28 [0.15,0.51] 0.39 [0.20,0.77]
p = 0.008
Cancer detection No 1,166 78.3 1,489 1.00 1.00
Yes 109 94.8 115 5.03 [2.19,11.55] 3.61 [1.48,8.85]
p = 0.001
Practice characteristics
Occupational Health Assessments No 342 72.6 471 1.00 1.00
Yes 907 82.6 1,068 1.79 [1.39,2.31] 1.68 [1.27,2.22]
p = 0.001
Actively involved in GP teaching No 865 82.5 1,049 1.00 1.00
Yes 392 73.4 534 0.59 [0.46,0.75] 0.61 [0.46,0.80]
p = 0.002
Run'Well man' clinic/appointments No 541 75.2 1,311 1.00 1.00
Yes 721 83.4 278 1.91 [1.31,2.77] 1.59 [1.06,2.39]
p = 0.064
Have a policy on PSA testing No 865 75.2 719 1.00 1.00
Yes 392 83.4 865 1.67 [1.31,2.13] 1.45 [1.11,1.90]
p = 0.007
Knowledge
PPV PSA level < 30% 472 71.6 659 1.00 1.00
Overestimated (> 30%) 743 84.5 879 2.16 [1.68,2.78] 2.02 [1.55,2.63]
p < 0.001
PPV PSA&DRE < 50% 310 69.8 444 1.00 1.00
Overestimated (> 50%) 912 83.0 1,099 2.11 [1.63,2.72] 2.06 [1.56,2.73]
p < 0.001
Clinical Practice
Refer 55 yr man at PSA level ≤ 7 ng/ml 803 82.9 969 1.00 1.00
≥ 7 ng/ml 332 74.9 443 0.62 [0.47,0.81] 0.60 [0.45,0.81]
Lab reference range 129 73.7 175 0.58 [0.40,0.84] 0.61 [0.40,0.93]
p = 0.002
Frequency of PSA testing: Annually or less Yes 457 94.2 485 6.01 [4.01,9.01] 5.54 [3.64,8.45]
No 793 73.1 1,085 1.00 1.00
p < 0.001
Perform other routine tests with PSA No 764 85.6 893 1.00 1.00
Yes 505 71.6 705 2.35 [1.83,3.01] 1.97 [1.51,2.57]
p < 0.001
Inform patient prior to testing Frequently 1,193 81.9 1,457 1.00 1.00
Sometimes 69 68.3 101 0.48 [0.31,0.74] 0.53 [0.31,0.89]BMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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[16], attendance at educational meetings on PSA had in
itself a negligible effect on practice, and furthermore level
of testing activity was not correlated with the GPs per-
ceived need for more information. However, information
on PSA testing and opinion of expert groups is often con-
flicting [35] and PSA has in general received a positive
press, with the various media campaigns [39] not dwell-
ing on the limitations of PSA as a tumour marker. Follow-
ing distribution of this survey, the National Cancer Forum
published 'A Strategy for Cancer Control in Ireland'
(2006) in which they recommended against the use of
PSA for population-based prostate cancer screening [40].
However, preliminary evidence suggests that this policy
has not affected the level of PSA testing in Ireland [11].
Improvements in the methods of dissemination of infor-
mation [41,42] and evaluation of the effectiveness of the
information may be necessary if public health policies are
going to impact on general practice.
A propensity to be influenced by a single incident, a diag-
nosis of prostate cancer by PSA testing, seemed to be cen-
tral to the belief system of the high screening GPs. Our
findings suggest that the GPs may be less inclined to trust
or apply "evidence-based" practice, feeling that it cannot
do justice to the heterogeneity of patients and pathology
in general practice, and trust more to their salient experi-
ence and "gut feelings". This, in the case of PSA testing,
seems a reasonable strategy. Most GPs will see on average
no more than one case of prostate cancer every 1.5 years
[43] and so the early diagnosis of a case can easily seem to
be a "success" for PSA testing, given the emphasis placed
on the early diagnosis of cancer. There are few, if any, neg-
ative implications for a GP in carrying out a test for diag-
nosing a cancer [8], while "missing" a cancer would be
seen as negligent [44,45] and would be a cause of deci-
sional regret for the doctor [46,47]. Fear of litigation in
such a case may also be a potent factor [48]. It is difficult,
in these circumstances, for a GP to put the "common
good" ahead of what seem to be the best interest of the
patient. In support of this, GPs perceive that the imple-
mentation of national guidelines in this area would afford
them some protection from litigation [12].
GPs who worked in the UK were more likely to test
asymptomatic men outside of the recommended age
groups. The reasons for this are unclear. Despite the fact
that guidelines do not recommend prostate cancer screen-
ing in the UK [22], awareness of these guidelines among
GPs was low [16,20]. Two studies have shown that they
did not influence the PSA testing or referral practices of
GPs [16,20] and there is evidence of prostate cancer
screening in the UK [2,34,49-51]. A survey of GPs in the
UK revealed that, similar to the findings of this study, 76%
of GPs would PSA test asymptomatic men [52]. One pos-
sibility is that GPs who worked or trained in the UK were
exposed to PSA in a clinical setting before those who did
not work outside of Ireland; the rate PSA testing peaked in
the mid-1990's in Northern Ireland [2] and Scotland [34],
while the increase in PSA testing in Ireland did not start
until after this time [9] and more than half of the labora-
tories in Ireland did not begin measuring PSA until post-
1995 [11].
Rarely/Never 9 27.3 33 0.08 [0.04,0.18] 0.09 [0.04,0.23]
p < 0.001
Had an asymptomatic man diagnosed with 
PCa via
PSA testing No 338 64.4 525 1.00 1.00
Yes 923 87.0 1,061 3.70 [2.87,4.76] 3.31 [2.51,4.37]
p < 0.001
Practice changed post PSA-detected PCa2 No 265 78.6 337 1.00 1.00
Yes 558 91.5 610 2.92 [1.98,4.29] 2.78 [1.81,4.25]
p < 0.001
Consider having a PSA test yourself3 No 48 37.8 127 1.00 1.00
Yes 807 85.7 942 9.80 [6.56,14.65] 8.25 [5.26,12.93]
p < 0.001
The multivariate model was fully adjusted for characteristics of the GP (age, gender, full-time principal, health board, whether they had qualifications 
in geriatric medicine, palliative care or occupational health, whether they trained in UK, whether they had a specialist interest in men's health, 
research, urological problems or cancer detection) and the practice (solo vs multi-doctor practice, percent of patients with private health 
insurance, percent of time performing Occupational Health Assessments, involvement in GP teaching, running a "well man" clinic, and having a 
practice policy on PSA testing).
1Length of time in practice was not adjusted for age because they were correlated.
2Among GPs who had an asymptomatic man diagnosed with prostate cancer via PSA testing (n = 1,061)
3Among male GPs (n = 1,088)
PPV = Positive Predictive Value.
PCa = Prostate Cancer
DRE = Digital Rectal Exam
Table 5: Factors significantly associated with the propensity of GPs to testing asymptomatic men (Continued)BMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
Page 9 of 12
(page number not for citation purposes)
Strengths and weaknesses
A major strength of this study is the large sample size and
the national coverage obtained. We have built a compre-
hensive multivariate model of a cohort of GPs only and
identified independent significant factors associated with
PSA testing, as well as calculating the magnitude of these
factors on PSA testing behaviour.
This survey was largely quantitative and could not explore
GPs' beliefs and motivations in depth. However, given
Table 6: Factors associated with PSA testing asymptomatic men < 50 and > 75 years.
yes Total Univariate Multivariate
Num % Num OR [95%CI] OR [95%CI]
GP Characteristics
Gender Male 564 65.1 867 1.00 1.00
Female 268 65.7 408 1.03 [0.80,1.32] 1.07 [0.82,1.41]
P = 0.615
Age group < 50 years 394 65.2 604 1.00 1.00
≥ 50 years 429 65.0 660 0.99 [0.79,1.25] 0.97 [0.75,1.26]
P = 0.513
Worked or trained in UK No 519 63.5 817 1.00 1.00
Yes 313 68.3 458 1.23 [0.97,1.58] 1.35 [1.05,1.74]
P = 0.020
Post-graduate qualifications
Occupational Health No 731 66.3 1,103 1.00 1.00
Yes 61 53.5 114 0.59 [0.40,0.86] 0.67 [0.45,1.00]
P = 0.051
MD No 824 65.8 1,252 1.00 1.00
Yes 8 34.8 23 0.28 [0.12,0.66] 0.30 [0.12,0.73]
P = 0.008
Clinical Practice
Lowest PSA level at which to refer a 55 yr old 
man for urological assessment
1.00 1.00
≤ 7 ng/ml 541 67.4 803
≥ 7 ng/ml 206 62.0 332 0.79 [0.61,1.03] 0.72 [0.54,0.95]
Lab reference range 77 59.7 129 0.72 [0.49,1.05] 0.74 [0.59,1.11]
P = 0.062
How often should a PSA test be performed in 
men aged ≥ 50 years?
Annually or less? No 472 59.5 793 1.00 1.00
Yes 347 75.9 457 2.15 [1.66,2.77] 2.08 [1.59,2.71]
p < 0.001 p < 0.001
Do you have a policy on PSA testing
No 345 62.3 554 1.00 1.00
Yes 487 67.5 721 1.26 [1.00,1.59] 1.36 [1.06,1.75]
p = 0.014
Do you perform other tests routinely with PSA
Yes 532 69.6 764 1.00 1.00
No 299 59.2 505 0.63 [0.50,0.80] 0.63 [0.49,0.81]
p < 0.001
Asymptomatic man diagnosed with PCa via PSA 
testing
Yes 617 66.8 923 1.27 [0.99,1.65] 1.24 [0.94,1.63]
No 207 61.2 338 1.00 1.00
p = 0.205
Consider having a PSA test yourself
No 23 47.9 48 1.00 1.00
Yes 541 66.1 819 2.15 [1.20,3.86] 2.02 [1.10,3.72]
p = 0.034
The multivariate model was fully adjusted for age, gender, health board, having more than 50% patients with private health insurance, having worked 
or trained in UK, having a policy regarding PSA testing and having an occupational health or an MD post-graduate qualification. PCa = prostate 
cancerBMC Family Practice 2009, 10:3 http://www.biomedcentral.com/1471-2296/10/3
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this limitation, some clear conclusions emerge. The main
potential limitation of the study was that the analysis was
based on GPs' self-reported PSA testing/screening behav-
iour. Our survey is therefore, subject to social bias
whereby GPs may perceive the correct answer to be that
they screen asymptomatic patients and themselves for
prostate cancer. However, the number of PSA tests has
increased 4-fold between 1999 and 2004 in Ireland and
the majority of requests originate in general practice [9].
Use of surveys raises the possibility of respondent bias.
When non-responders were analysed, they were signifi-
cantly more likely to test asymptomatic men and to test
asymptomatic men outside the appropriate age groups,
than responders to the initial survey. Therefore, the PSA
testing behaviour of responders may be more conservative
than that of non-responders.
There are numerous mediolegal pitfalls in the diagnosis of
prostate cancer [45], and indeed these were raised by a
number of respondents [12], however, we did not investi-
gate this factor as a potential predictor of GP testing
behaviour. Further research is required into the influence
of mediocolegal factors on PSA testing behaviour.
We found that attending educational meetings where PSA
testing was a major topic had no effect on the PSA testing
practice of GPs responding to this survey. However, we do
not have any information about the structure and content
of these meetings or indeed about who organized and
sponsored them – all of which could potentially influence
their effectiveness.
GPs who reported that they had a policy on PSA testing
were significantly more likely to report that they would
PSA test asymptomatic men, both within and outside the
appropriate age groups. However, we do not know the
details of the policies, the reasons for implementing them
or the evidence used to inform them. This requires further
research and is potentially an area of GP practice which
could be targeted to effect change in PSA testing practice.
Recommendations
Highlighted in this study is the need for further education
and support for GPs concerning prostate cancer screening
and the disconnection between the scientific literature on
the value of PSA and clinical practice. Given the increase
in patient knowledge, emphasis on evidence-based medi-
cine and shared decision-making, there is a need for both
doctor and patient to be fully informed [53]. This raises
important questions and challenges regarding knowledge
translation. The first step in closing the evidence-to-prac-
tice gap [41,42,54] usually involves developing evidence-
based policy or guidelines. While the majority of GPs in
our study agreed that there was a need for national guide-
lines on PSA testing in Ireland, as discussed it is unlikely
that these alone would influence practice [16,20]. The
lack of success of guidelines in changing the practice of
health care providers may result from the passive dissem-
ination of guidelines and policy [55] and more active
approaches such as audit and feedback, reminders and
educational outreach [56] are needed. In parallel, a pro-
gramme of public education, along with methods to eval-
uate their effectiveness, and research into how men in
Ireland are making decisions about prostate cancer screen-
ing is warranted, given the impact men's beliefs have on
their decision to have a PSA test [57].
Conclusion
Addressing this gap between evidence and practice needs
a closer study of how GPs handle evidence; are GPs'
poorly informed because of lack of opportunity, poor dis-
semination strategies or, having had a significant incident,
do they make their minds up and cease to register any con-
flicting evidence? Do some GPs drift into testing, while
others research the evidence before beginning? Our
knowledge of the factors which bridge the gap between
evidence and GPs beliefs, attitudes and practice remains
rudimentary. Overall the belief of GPs in the clinical util-
ity of PSA testing asymptomatic men, despite the lack of
evidence that it improves outcome, has major implica-
tions for policy makers. If there is to be any hope of more
evidence-based practice in this area, there is an urgent
need to identify specific barriers to evidence-based deci-
sion making and to develop effective interventions and
strategies to influence clinical practice and/or encourage
adherence to evidence-based guidelines and policy.
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